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Abstract 12 
Ivermectin is a gold-standard antiparasitic drug that has been used successfully to treat billions of 13 
humans, livestock and pets. Until recently, the binding site on its Cys-loop receptor target had 14 
been a mystery. Recent protein crystal structures, site-directed mutagenesis data and molecular 15 
modelling now explain how ivermectin binds to these receptors and reveal why it is selective for 16 
invertebrate members of the Cys-loop receptor family. Combining this with emerging genomic 17 
information, we are now in a position to predict species sensitivity to ivermectin and better 18 
understand the molecular basis of ivermectin resistance. An understanding of the molecular 19 
structure of the ivermectin binding site, which is formed at the interface of two adjacent subunits 20 
in the transmembrane domain of the receptor, should also aid the development of new lead 21 
compounds as both anthelmintics and as therapies for a wide variety of human neurological 22 
disorders.  23 
 24 
New insight into a wonder drug 25 
Orally- or topically-administered ivermectin is used to eliminate parasitic nematodes and 26 
arthropods from animals and humans[1]. It is effective yet well-tolerated due to the potency with 27 
which it activates a uniquely invertebrate member of the Cys-loop receptor family of ligand-gated 28 
ion channels[2]. Although the activation of Cys-loop receptors by neurotransmitter agonists has 29 
been studied in molecular detail for 20 years, the ivermectin interaction with these receptors has 30 
received relatively little attention. This interaction requires attention, given the evidence that 31 
ivermectin resistance can occur via mutations that affect the ivermectin sensitivity of Cys-loop 32 
receptors [3,4]. In the last year, the binding sites of ivermectin in nematode and human Cys-loop 33 
receptors have been identified, revealing key molecular determinants of ivermectin sensitivity. 34 
Coinciding with these discoveries, a growing number of complete genomes have revealed the 35 
Cys-loop receptor complements of species of known ivermectin susceptibility. Combining this 36 
knowledge should allow the prediction of ivermectin sensitivity, help understand resistance 37 
mechanisms and inform the development of broader spectrum antiparasitic drugs. Recent insights 38 
in this area are reviewed here, following a brief introduction concerning the use of ivermectin and 39 
the structural basis of Cys-loop receptor function. 40 
 3 
 41 
Origins of ivermectin 42 
Intensive screening of soil-dwelling microbes in the 1970s led to the isolation from the 43 
bacterium, Streptomyces avermectinius, of a group of natural macrocyclic lactones with potent 44 
nematicidal activity, named avermectins [5]. Saturation of the avermectin 22-23 double bond 45 
produced 22,23-dihydroavermectin B1, or ivermectin. Ivermectin consists of a mixture of B1a 46 
and B1b components in a 80:20 ratio. These compounds vary in structure only at C25, a moiety 47 
that is not involved in binding. As the B1a component is more lethal to nematode, insect and 48 
acarid parasites [1], it is conventional to refer to either the mixture or the B1a component as 49 
‘ivermectin’.  Much attention has been paid to the use of ivermectin against Onchocerca volvulus, 50 
a mosquito-transmitted parasitic nematode that causes river blindness, but its use now extends to 51 
other human diseases including lymphatic filariasis, strongyloidiasis, scabies and head lice [1]. 52 
Despite its broad antiparasitic spectrum, ivermectin is ineffective against platyhelminths [6,7], 53 
including the blood fluke Schistosoma mansoni which causes bilharzia [8].  54 
 55 
Ivermectin targets Cys-loop receptors 56 
Early investigations into the lethal effect of ivermectin on arthropods and nematodes showed that 57 
ivermectin increased chloride conductance in neurons and thus decreased responses of neurons to 58 
excitatory input [9,10]. The search for the identity of this conductance led to the cloning of two 59 
novel subunits from the free-living nematode Caenorhabditis elegans that formed a recombinant 60 
glutamate-gated chloride channel (GluClR) that was activated irreversibly by nanomolar 61 
ivermectin concentrations [2]. Numerous GluClR subunits have since been cloned in various 62 
ivermectin-susceptible invertebrates [11,12]. The identification of GluClRs as the target of 63 
ivermectin was confirmed by their high ivermectin sensitivity when expressed recombinantly, 64 
their expression in tissues sensitive to low doses of ivermectin, and the development of 65 
ivermectin resistance upon their mutation [3,4,12-15]. GluClRs belong to the Cys-loop receptor 66 
family of ligand-gated channels, which includes human excitatory nicotinic acetylcholine and 67 
type-3 5-hydroxytryptamine receptors (nAChRs and 5-HT3Rs) and inhibitory GABA type-A and 68 
glycine receptors (GABAARs and GlyRs). 69 
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The Cys-loop receptor family is large, with 102 subunits in C. elegans and 45 in humans [16,17]. 70 
Numerous inhibitory receptors in this family are activated by ivermectin, including arthropod 71 
histamine-gated chloride channels (HisCls) and pH-gated chloride channels (pHCls) and, perhaps 72 
unexpectedly, human GABAARs and GlyRs. A deciding factor in the combined lethality in 73 
nematode/arthropod parasites and safety in mammalian hosts is the differential potency with 74 
which ivermectin activates these receptors. α GluClRs are typically activated by low (< 20) 75 
nanomolar concentrations [2,14,18,19], whereas GABAARs and GlyRs require concentrations in 76 
the low (1-10) micromolar range [20-23]. HisCls and pHCls respond to micromolar ivermectin, 77 
but the dose dependency has not been established [24-26]. At several other receptors, ivermectin 78 
activates no current but modulates (inhibits or potentiates) the responses to the neurotransmitter 79 
agonist. These include some invertebrate GABAARs and the human α7 nAChR (below).. 80 
The sensitivity of human Cys-loop receptors to micromolar ivermectin, along with the 81 
preliminary findings of anti-spasticity efficacy in humans [28], begs the question as to what 82 
concentration reaches in the brain. Therapeutic doses in mice, dogs and humans produce plasma 83 
levels of 5-10 nM that persist for days, with ~2 nM in the brain [29-31], which is insufficient to 84 
activate GABAARs and GlyRs. When α GluClRs are exogenously expressed in the mouse brain, 85 
animals respond to systemic ivermectin [32], indicating that ivermectin safety rests on the 86 
reduced sensitivity of mammalian Cys-loop receptors. P-glycoprotein, which transports 87 
avermectins out of the nervous system, is also crucial to ivermectin potency in mammals and 88 
nematodes, evidenced by the increased ivermectin toxicity that results upon its mutation [33,34]. 89 
 90 
Structure-activity relationships in Cys-loop receptors and ivermectin 91 
Before describing in detail the structural features that determine ivermectin sensitivity, we briefly 92 
outline the structural basis of function in Cys-loop receptors and the determinants of efficacy 93 
within the ivermectin molecule. Functional Cys-loop receptor pentamers are formed by five of 94 
the same or, as is usually the case for native receptors, two to three different subunits (Figure 95 
1a,b). A single subunit consists of: a large extracellular N-terminal domain (ECD) and four 96 
membrane-bound helices (M1-M4) that constitute the transmembrane domain (TMD). Two 97 
highly conserved ECD Cys residues are crosslinked within a functional receptor, forming the 98 
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eponymous Cys-loop, and the apposition of five M2 helices forms the central channel pore 99 
(Figure 1b,c). Neurotransmitter ligands bind at the extracellular interface of two adjacent subunits 100 
(red segments in Figure 1b), resulting in the closure of binding domain loop C around the agonist. 101 
This triggers structural rearrangements at the ECD-TMD interface (purple segments in Figure 102 
1b), and ultimately the opening of the channel gate (Figure 1c,d), allowing ions to flow through 103 
the channel [35]. This chemoelectric signalling mechanism underlies most rapid synaptic 104 
transmission in the brain. 105 
The structural basis of activity of avermectins and milbemycins (Streptomyces spp-derived 106 
compounds with similar structures and antiparasitic spectra to avermectins) has been extensively 107 
reviewed[36]. Briefly, all compounds share a macrocyclic backbone and differ at the 108 
disaccharide, spiroketal and benzofuran moieties, respectively located at the three “corners” of 109 
the molecule (Figure 2). Evidence indicates that the benzofuran is the most important potency 110 
determinant at GluClRs. For example, substitution of the hydroxyl at the C5 position on the 111 
benzofuran ring ("C5-OH") for oxime or ketone in several avermectins reduces nematicidal 112 
activity 100- and 10000-fold, respectively [37], implying that either an H-bond donating or 113 
generally hydrophilic C5-substituent is required for high potency. In contrast, changes to the 114 
spiroketal group have little effect on nematicidal potency [36,37]. Similarly, hydrogenation of 115 
double bonds C10-C11 (in the macrocyclic backbone) and 22-23 (in the spiroketal) does not 116 
reduce acaricidal potency, whereas hydrogenation of double bonds C3-C4 and C8-C9 (in or 117 
adjacent to the benzofuran) reduces both acaricidal potency and activity at mouse GABAARs 118 
[38,39]. The sugar moiety is not essential for nematicidal potency [36,37]. However, given that 119 
epimerisation of the dissacharide decreases activity at GluClRs [40,41], polar C13 substitutions 120 
yield less biologically active avermectins than lipophillic C13 substitutions [42], and size of the 121 
sugar moiety correlates with affinity for P-glycoprotein [43], it is evident that the sugar may 122 
modulate avermectin potency in vivo. 123 
 124 
The binding site in anionic Cys-loop receptors 125 
Hibbs and Gouaux recently solved the crystal structure of the C. elegans α GluClR complexed 126 
with ivermectin [44]. This gives a clear picture of the ivermectin binding site and sheds light on 127 
previous functional studies. Furthermore, with over 30 % amino acid sequence identity with the 128 
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α1 GlyR, it provides a high resolution template for the modelling of vertebrate GABAARs and 129 
GlyRs, which had previously relied on nAChR and prokaryotic receptor structures with much 130 
lower homologies [45-47]. Their structure shows ivermectin binding between the M3 of one 131 
subunit (the principal or (+) face) and the M1 of an adjacent subunit (the complementary or (-) 132 
face), with the benzofuran moiety contacting the M2 helix of the (+) subunit (Figure 3a). The 133 
structure implies the existence of three H-bonds: (i) between the benzofuran C5-OH and the 134 
hydroxyl sidechain of (+)M2-Ser15' (Ser260 in the α GluClR), (ii) between a spiroketal oxygen 135 
and the hydroxyl sidechain of (+)M3-Thr285, and (iii) between the benzofuran C7-OH and the 136 
backbone carbonyl oxygen of (-)M1-Leu218 (Figure 3b). Leu218, Ser260 and Thr285 are 137 
highlighted in yellow in Figure 3c, as are residues at the equivalent positions in various other 138 
Cys-loop receptors. Twelve other sidechains, highlighted in orange or red in Figure 3c, contribute 139 
potential Van der Waals interactions. One of these is (+)M3-Gly281, a position in anionic Cys-140 
loop receptors we will henceforth refer to as "M3-Gly". M3-Gly is entirely conserved in GluClRs 141 
that show nanomolar ivermectin sensitivity (Figure 3c). In the crystal structure, the α carbon of 142 
M3-Gly is approximately 4.5 Å from each corner of the ivermectin macrocycle, such that any 143 
larger sidechain at this position - that is, any amino acid other than Gly - would hinder the access 144 
of ivermectin to its binding site or alter the binding conformation of ivermectin (Figure 3b). 145 
Hence, in the Haemonchus contortus α3B GluClR, the mutation of M3-Gly to Ala (the human α1 146 
GlyR equivalent) shifts the ivermectin EC50 for activation from 39 nM up to 1.2 µM - exactly that 147 
of the human α1 GlyR [48]. Indeed, the α3B GluClR and the α1 GlyR can be tuned to 148 
remarkably similar ivermectin sensitivities by introducing a common residue at the M3-Gly 149 
position [48]. Consistent with this, the Gly323Asp mutation (at the M3-Gly position) in the 150 
Tetranychus urticae (two-spotted spider mite) GluClR was shown to increase by 18-fold the 151 
avermectin dose required for half-maximal lethality [4]. Indeed, the equivalent Gly-Asp 152 
substitution abolished binding of a tritiated milbemycin to the α3B GluClR [49]. We have not 153 
found in the literature any example of a highly ivermectin-sensitive receptor without a Gly at the 154 
M3-Gly position. 155 
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The binding site at the α1 GlyR has also been investigated using mutagenesis and molecular 156 
modelling. Ivermectin was modeled as wedging into the same TMD interface, with the 157 
benzofuran oriented towards the (+)M2 [50]. Surprisingly, the docking of ivermectin to the 158 
Ala288Gly α1 GlyR (this is the M3-Gly position) did not differ greatly from the unmutated 159 
receptor, suggesting that the on-rate of ivermectin, rather than the ultimate binding conformation 160 
of ivermectin, is changed by this substitution [50]. Alternately, the glycine substitution may 161 
increase the gating equilibrium constant, thus facilitating receptor activation by ivermectin. Bulky 162 
substitutions at only two positions decreased both agonist and modulatory effects of ivermectin, 163 
indicative of a decisive role in binding. These positions are (+)Ala288 and (-)Pro230. Both of 164 
these positions are highlighted in red in Figure 3c, revealing the apparent requirement of a small 165 
residue at the M3-Gly position and the conservation of the "M1-Pro". M1-Pro is in close 166 
proximity to the crucial benzofuran moiety of ivermectin (Figure 3b), providing a possible steric 167 
explanation for decreased binding at this mutant. In addition, this highly conserved residue 168 
disrupts M1 helical structure thereby exposing a backbone carbonyl that is thought to form a H-169 
bond with the ivermectin C7-OH [44]. However, the existence of this bond requires confirmation, 170 
given that C7-OH is equidistant from both the M1 backbone carbonyl and the endogenous 171 
ivermectin C1 carbonyl. 172 
A significant role for the third putative H-bond (between O14 and T285 – see Figure 3b) can be 173 
eliminated on the basis of site-directed mutagenesis experiments in the Ala288Gly α1 GlyR, and 174 
the fact that the three GluClRs with nanomolar ivermectin affinity do not contain H-bonding 175 
sidechains at the corresponding M3 position [50]. Moving deeper into the pore, substitution of α1 176 
GlyR (+)M3-Leu291, (+)M2-Thr264 or (-)M1-Leu233 for bulky Trp sidechains does not reduce 177 
ivermectin sensitivity but converts ivermectin from an agonist to an antagonist of glycine-178 
activated currents [50]. Still further removed from the binding site, mutations in the conserved 179 
Cys-loop, the pre-M1 domain and the M2-M3 linker (Figure 1b) decrease ivermectin potency 180 
most likely by impairing its gating efficacy [14,18,49-51]. 181 
Native Cys-loop receptors are often heteromeric and thus do not necessarily possess the five 182 
binding sites available to ivermectin in homomers. The following evidence at the GlyR, however, 183 
suggests that the binding of two molecules of ivermectin is sufficient for either direct activation 184 
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or potentiation. First, ivermectin activates α1β heteromeric and α1 homomeric GlyRs with equal 185 
potency [21], even though heteromers possess a β-α1-β-α1-β arrangement [52] and ivermectin 186 
only binds to the (+)α1/(-)β interface [48]. Second, the β-Ile312Gly substitution (at the M3-Gly 187 
position) confers sensitivity to potentiation on the otherwise ivermectin-insensitive α1-188 
Ala288Phe/β heteromer, presumably by introducing a (+)β/(-)α1 ivermectin binding site [48].  189 
 190 
M2 H-bonds 191 
The putative H-bond between the ivermectin C5-OH and the M2-15' Ser of the GluClR and GlyR 192 
seems a logical ivermectin binding interaction, as (i) it links the ivermectin molecule to the pore-193 
lining M2 helix[44] and (ii) a H-bond donor at the C5-OH is crucial to avermectin nematicidal 194 
potency (above). However, because various GluClRs with nanomolar ivermectin sensitivities 195 
contain either an Ala or Ile at this position (Figure 3c), it is evident this H-bond is not required for 196 
high ivermectin potency [4,18,53]. In support of this, the mutant M2-Ser15'Ile substitution in the 197 
α1 GlyR causes no change to the agonist or modulatory effects of ivermectin [50]. However, 198 
most anionic Cys-loop receptor subunits possess several nearby residues that could act as 199 
potential H-bond acceptors in the absence of one at the M2-15' position. These include (+)M2-200 
12', (-)M2-14', (+)M2-19' and also an (-)M1 position (Figure 4). The proximity of these 201 
sidechains to the ivermectin molecule is suggested by site-directed mutagenesis data from the α1 202 
GlyR: the Thr12'Trp receptor is not activated by ivermectin, the Gln226Cys receptor has 203 
decreased ivermectin sensitivity and the Gln266Trp receptor has increased sensitivity [50]. The 204 
conservation of polarity in this domain of ivermectin-sensitive receptors is illustrated by the 205 
boxed residues in Figure 3c.  206 
 207 
A clear pattern? 208 
We now group the above ivermectin sensitivity determinants together and consider their chemical 209 
properties in several receptors with known high ivermectin sensitivity. Dividing M2-12', M2-14', 210 
M2-15', M2-19' and the M1-Gln residue into their (+) and (-) components gives a "(+)Thr-Ser-211 
Arg/(-)Gln-Gln" arrangement, in the case of the α1 GlyR (Figure 4). The following five 212 
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homomeric Cys-loop receptors are particularly sensitive to ivermectin activation (i.e., activated 213 
by 1-20 nM ivermectin): Ala288Gly α1 GlyRs, C. elegans α, H. contortus α and α3B and 214 
Drosophila α GluClRs. Respectively, these subunits have (+)Thr-Ser-Arg/(-)Gln-Gln, (+)Thr-215 
Ser-Asp/(-)Gln-Gln, (+)Thr-Ala-Asn/(-)Gln-Gln, (+)Thr-Ala-Asn/(-)Gln-Gln and (+)Ala-Thr-216 
Asn/(-)Gln-Gln arrangements, and thus present an overwhelmingly polar environment to the 217 
ivermectin C5-OH moiety. Given that the α1 GlyR possesses a similar polarity in this region to 218 
GluClRs, we infer that its large M3-Gly sidechain is solely responsible for its reduced ivermectin 219 
sensitivity. UNC-49B/UNC-49C heteromeric GABAARs possess an M3-Gly at the (+) faces of 220 
UNC-49C, yet are not activated by ivermectin [54,55]. However, with a (+)Thr-Met-Asn/(-)Gln-221 
Leu arrangement, they are distinct from the GluClRs and GlyRs in that both the M2-14' and M2-222 
15' positions are occupied by larger hydrophobic residues (Figure 3c), perhaps limiting H-bonds 223 
with and channel activation by ivermectin [44]. Similarly, the Dermacentor variabilis (American 224 
dog tick) homomeric RDL receptor possesses an M3-Gly but is not sensitive to ivermectin 225 
(Figure 3), and its M2-14' and M2-15' positions are occupied by hydrophobic residues [56]. By 226 
contrast, MOD-1 is insensitive to ivermectin [57], despite its ostensibly suitable (+)Thr-Ser-227 
Arg/(-)Gln-Ile arrangement; MOD-1 insensitivity is likely due to a Val residue at the M3-Gly 228 
position preventing access to the site [50]. Curiously, although mammalian GABAAR π subunits 229 
possess an M3-Gly, incorporation of the π subunit actually decreased the ivermectin sensitivity of 230 
α1β2 GABAARs [48]. Again we suggest that the ivermectin-insensitivity results from 231 
hydrophobic residues at both M2-14' and M2-15' positions in the π subunit [58]. Finally, 232 
functional homomeric β GluClRs from C. elegans and C. onchophora are also completely 233 
insensitive to ivermectin [59], and studies with radiolabelled ivermectin show that it does not 234 
even bind to the H. contortus β GluClR [60]. These receptors contain a (+)Thr-Gln-Asn/(-)Gln-235 
Met arrangement and an M3-Gly. We thus conclude that the (-)M1-Met is responsible for 236 
disrupting ivermectin sensitivity. In the above analysis, we have used the GluClR crystal 237 
structure to infer that the five polar residues are essential for high ivermectin affinity. However, it 238 
is also possible that the overwhelmingly polar environment facilitates receptor gating by 239 
ivermectin.  240 
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An alternate possibility in GABAARs is that ivermectin binds to a different site. For example, 241 
GAB-1/HG1A heteromers and UNC-49B homomers possess Val, Leu or Asn residues at the M3-242 
Gly position, and these receptors are potentiated but not activated by ivermectin [54,55,61], 243 
perhaps reflecting the exclusion of ivermectin from the interfacial site and the existence of an 244 
alternate site. Moreover, HG1A and HG1E differ by only four amino acids - in the ECD and in 245 
M4 - and, whereas GAB1/HG1A heteromers are potentiated by ivermectin, GAB1/HG1E 246 
heteromers are inhibited [61]. An alternative site, consistent with HG1A/E structural differences, 247 
might be similar to that proposed for the mammalian α7 nAChR (see below). The possibility of 248 
distinct ivermectin binding sites in various GABAARs, together with the large diversity in 249 
GABAAR subunits, might underlie the differential effects of ivermectin on various native 250 
GABAAR preparations [62]. 251 
 252 
An alternative site for potentiation of nAChRs 253 
Due to the differing M2-M3 domain lengths in anionic and cationic Cys-loop receptors, it is 254 
difficult to determine which amino acid occupies the M3-Gly position in the mammalian α7 255 
nAChR [63]. Most alignments suggest that Ala275 in the α7 nAChR and Leu279 in the Torpedo 256 
marmorata (marbled electric ray) nAChR α subunit occupy the M3-Gly position. Although the 4 257 
Å resolution structure of the T. marmorata nAChR places this Leu279 in the (+)M3 helix, it faces 258 
the outside of the membrane, 1-2 helical turns above the level of (-)M1Pro (Figure 5a). In the T. 259 
marmorata nAChR structure, the (+)M3 residue physically opposite (-)M1-Pro is either Met282, 260 
Ile283 or Ile286, which equate with little ambiguity to Met278, Ile279 and Gly282 in the α7 261 
nAChR (Figure 5a,b). Thus, the α7 nAchR structural equivalent to the M3-Gly might Gly282, 262 
and the selectivity of ivermectin for α7 nAChRs over insensitive cationic Cys-loop receptors may 263 
be due to Val, Ile and Thr sidechains at this position (e.g., in nematode ACR-16 receptors and 264 
mammalian 5-HT3Rs [64,65]). Accordingly, the lack of H-bond propensity at M2-14', M2-15' and 265 
M2-19' positions in the α7 nAChR might limit the direct agonist efficacy of ivermectin. 266 
However, if the structural equivalent in α7 nAChR is Met278 or Ile279, access of ivermectin to 267 
the interfacial site is likely precluded, and ivermectin might bind to a distinct site. 268 
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Computer docking simulations from two separate laboratories have shown that the lowest energy 269 
docking of ivermectin to the α7 nAChR was in an intrasubunit cavity, as opposed to the 270 
interfacial site in anionic receptors [64,66]. In both studies, the ivermectin molecule wedges 271 
between M1 and M4 from the same subunit, partly in contact with the surrounding lipids, with 272 
the benzofuran moiety oriented towards either M2 or M3 of the same subunit. Substitution of α7 273 
nAChR TMD residues for the non-conserved equivalents from the 5-HT3AR resulted in decreased 274 
potentation by ivermectin or conversion of potentiation to inhibition [64]. Three of the four 275 
mutations that simply decrease potentiation line a space between M1 and M4 of the one subunit, 276 
albeit two helical turns below the docked ivermectin molecule. Consistent with putative existence 277 
of this site in the α7 nAChR and not in GluClRs and GlyRs, the latter possess large sidechains 278 
that might obscure this cavity (Figure 5). Finally, the effects of ivermectin at nAChRs are 279 
reversible and are decreased by ECD-acting competitive antagonists [67], which differs from 280 
results at most anionic receptors and supports a different site or mechanism of ivermectin at 281 
nAChRs. 282 
 283 
Structural bases of ivermectin resistance 284 
There are several reports that ivermectin resistance occurs nematodes in natural settings [1], in 285 
some cases due to mutations in the coding sequences or changes in expression levels of GluClRs 286 
or GABAARs [3,68,69]. In laboratory-induced mutant strains, single mutations in GluClRs have 287 
been clearly shown to cause avermectin resistance. For example, mutation of the M3-Gly position 288 
in the T. urticae GluClR causes an 18-fold increase in abamectin LD50 [4]. (A C22-C23 double 289 
bond in the spiroketal of abamectin is the only difference from ivermectin.) It is also possible that 290 
ivermectin insensitivity may be caused by mutations that allosterically disrupt the efficacy with 291 
which ivermectin activates the receptors, without necessarily affecting ivermectin affinity. This 292 
was first suggested by an M2-M3 linker mutation in a Drosophila GluClR that caused a four-fold 293 
increase in ivermectin LD100 [14]. Disruptions to the efficacy of GluClR gating by ivermectin 294 
most likely account for the effects of mutations identified in several resistant H. contortus strains 295 
[18,49]. Of course, if a GluClR mutation converts ivermectin to an inhibitor, as demonstrated at 296 
recombinant GlyRs and nAChRs (above), the usual CNS depression elicited by ivermectin could 297 
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be converted to excitation. This may underlie the resistance seen in nematodes with an up-298 
regulation of HG1E GABAAR subunits that are inhibited by ivermectin [61,68].  299 
 300 
Predicting species susceptibility to ivermectin 301 
The discovery of molecular determinants of ivermectin sensitivity in Cys-loop receptors provides 302 
an opportunity to investigate parasites of known ivermectin susceptibility to establish the 303 
molecular basis for this susceptibility. The complete genome of the trematode S. mansoni reveals 304 
13 Cys-loop receptor subunits [70], much fewer than the 102 found in C. elegans and 45 in 305 
humans [16,17]. It is therefore likely that ivermectin has fewer potential Cys-loop receptor targets 306 
in S. mansoni than in C .elegans  which might help explain why S. mansoni is insensitive to 307 
ivermectin. On the other hand, arthropods also possess few GluClRs but are ivermectin-308 
susceptible, suggesting that there must be some feature of S. mansoni GluClRs (other than a small 309 
number in the genome) that renders them insensitive to ivermectin. An amino acid sequence 310 
alignment of recently available transcripts in several trematodes suggests that they indeed possess 311 
GluClRs (Figure 6). Although their functional properties remain to be investigated, these 312 
transcripts possess ~30 % homology with α GluClRs and α1 GlyRs, suggesting a functional 313 
relationship. Furthermore, they possess a Gly residue on the (+) face of the ECD neurotransmitter 314 
binding domain (Figure 6), at a position where small residues are correlated with Glu binding and 315 
larger residues are correlated with Gly, GABA or His binding[71]. These putative GluClRs 316 
include largely polar (+)Ile-Ser-Ala/(-)Ser-Gln arrangements (as per the scheme above), but large 317 
residues at the M3-Gly position undoubtably preclude ivermectin binding (Figure 6). Thus, large 318 
sidechains at the M3-Gly position, as opposed to a lack of GluClRs, may well underlie the 319 
ivermectin-insensitivity of trematodes. The free-living trematode Schmidtea mediterranea also 320 
possesses GluClR-like transcripts with large sidechains at the M3-Gly position (Figure 6). The 321 
recent sequencing of Ascaris suum (pig roundworm), Anopheles gambiae (mosquito) and 322 
Daphnia pulex (water flea), by contrast, reveal one or more M3-Gly GluClR transcripts, as 323 
expected for ivermectin-susceptible phyla [72-74]. This reiterates the importance of the M3-Gly 324 
position. Of course, species susceptibility also depends on if and where the relevant subunits are 325 
expressed, and the functionality with which an M3-Gly subunit heteromerises with other 326 
subunits. 327 
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 328 
Concluding remarks 329 
Ivermectin binds to nematode GluClRs and mammalian GlyRs at the interface of adjacent (+) and 330 
(-) subunits in the TMD of the receptor. High affinity for this site is controlled by an M3 Gly 331 
residue on the (+)M3 helix that allows rapid access to the site. The C5 hydroxyl of the ivermectin 332 
benzofuran likely forms an H-bond within the subunit interface cleft, leading to potent channel 333 
activation. Potent activity requires polar sidechains at either M2-14', M2-15' or M2-19' (and 334 
perhaps other) positions. Scanning Cys-loop receptor amino acid sequences for these 335 
determinants predicts ivermectin sensitivity reasonably well, and scanning genomes for these 336 
transcripts may enable the prediction of species susceptibility to ivermectin. However, several 337 
questions are yet to be answered, including the structural basis for modulation (not activation) by 338 
ivermectin of certain GABAARs and nAChRs, and the inability of ivermectin to activate β 339 
GluClRs. Attempts to answer these questions will be aided by the structural template provided by 340 
the GluClR crystal structure. Given the emergence of ivermectin resistance in parasitic nematode 341 
pests [75,76], the information presented here may help in the design of novel anthelmintics 342 
targeting GluClRs or other nematode Cys-loop receptors. Similarly, because ivermectin binding 343 
sites also exist in human Cys-loop receptors, understanding the ivermectin binding site structure 344 
may help identify new therapeutic pharmacophores for a wide variety of human neurological 345 
disorders. 346 
347 
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Figure legends 348 
Figure 1. Molecular architecture of Cys-loop receptors. (a) The C.elegans α GluClR crystal 349 
structure, viewed from the extracellular space (top panel) and from within the lipid membrane 350 
(lower panel) [44]. (b) Single subunit from (a). Red indicates segments that contribute to the 351 
neurotransmitter binding domain, which is formed between the (+) face of one subunit and the (-) 352 
face of an adjacent subunit; magenta indicates Loop 2, the conserved Cys-loop, the pre-M1 353 
domain, and the M2-M3 linker, which couple neurotransmitter binding to channel movement; 354 
helices M1-M4 are indicated; M2-Leu9' sidechains that contribute to the channel gate are shown 355 
as blue spheres [35]. (c) Crystal structure of the closed bacterial channel ELIC [46] and (d) 356 
crystal structure of the open bacterial channel GLIC [45], both viewed from the extracellular 357 
space with ECDs removed for clarity; the hydrophobic M2-9' sidechain is moved from the 358 
channel axis in models of channel activation. 359 
 360 
Figure 2. The ivermectin molecule. (a) Natta projection of ivermectin, including the C atom 361 
numbering referred to in the text. (b) 3D structure of ivermectin, as used for docking to the α1 362 
GlyR model[50]. Certain atoms/substituents are labelled, for comparison with (a) or for their 363 
significance in the text. Image in (b) prepared with PyMOL Molecular Graphics System 364 
(Schrödinger, LLC). 365 
 366 
Figure 3. Ivermectin binding sites and sensitivity determinants in anionic Cys-loop receptors. (a) 367 
The ivermectin binding site in the C. elegans α GluClR [44]. Adjacent (+) and (-) subunits are 368 
shown in grey and black, respectively, with M2 domains from the remaining three subunits 369 
shown in blue and all ECDs removed for clarity. Yellow lines indicate H-bonds with indicated 370 
residues. Orange positions indicate residues that form Van der Waals interactions with the 371 
ivermectin molecule. (b) The same site as in (a), but viewed from (+)M2-Ser260 (15'). Red lines 372 
indicate proximity of Pro230 (3.4 Å) and Gly281 (4.0 and 4.5 Å) to ivermectin; yellow lines 373 
indicate H-bonds with (-)Leu218 and (+)Thr285. (c) Amino acid sequence alignment of TMD 374 
portions of Cys-loop receptor subunits of known ivermectin sensitivity. Orange and red (Van der 375 
Waals interactions) and yellow (H-bonds) highlighting indicates residues that line the site, as in 376 
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(a) and (b); boxed residues constitute the polar binding site for the ivermectin benzofuran in 377 
ivermectin-sensitive receptors (see text and Figure 4). Cel, Caenorhabditis elegans; Hco, 378 
Haemonchus contortus; Dme, Drosophila melanogaster; Tur, Tetranychus urticae; Hsa, Homo 379 
sapiens; Ssc, Sacrcoptes scabiei; Dme, Dermacentor variabilis; Mmu, Mus musculus. "nM" and 380 
"µM" (nanomolar and micromolar) indicate the concentration range in which receptors of that 381 
subunit are robustly activated by ivermectin. "mod" (modulatory) means that the receptor is not 382 
activated but is potentiated or inhibited by micromolar concentrations of ivermectin. *The T. 383 
urticae α GluClR confers ivermectin susceptibility on the organism [4]; it is therefore considered 384 
highly ivermectin-sensitive although the recombinant receptor has not been tested. **The 385 
recombinant D. variabilis RDL has only been exposed to 100 nM ivermectin, which had no 386 
agonist or modulatory effect [56]. Lines joining subunits indicate that these form heteromeric 387 
receptors. References for all subunits listed are provided in the main text, except for Cel GluClR 388 
α2B [77] and Cel GLC-3 [78]. 389 
 390 
Figure 4. Possible H-bond partners of the ivermectin C5-hydroxyl. The ivermectin binding site in 391 
an α1 GlyR homology model [50], viewed from the (+)M3 helix, with the (+)M3 helix removed. 392 
Distances (yellow lines) are 8.1, 2.9, 4.0, 3.3 and 10.1 Å, clockwise from M2-12'. 393 
 394 
Figure 5. Comparison of an intrasubunit site in nAChRs and anionic Cys-loop receptors. (a) 395 
TMD portions of adjacent (+)α and (-)γ subunits of the Torpedo marmorata ("Tma") nAChR 396 
(left; electron microscopy structure [47]) and of adjacent subunits of the C. elegans α GluClR 397 
(right, [44]), seen from within the membrane plane. For each receptor, the (+) subunit is shown in 398 
light grey, the (-) subunit in dark. nAChR α Leu279 (green) aligns with the GluClR M3-Gly 399 
position in most amino acid sequence alignments, but Met282, Ile283 (yellow) and Ile286(red) 400 
are structurally more equivalent to GluClR M3-Gly, indicated by the proximity to M1-Pro (red in 401 
both receptors). Shown in magenta are several residues that line a space between M1 and M4 of 402 
each subunit (these are equivalent in amino acid alignments but were selected simply due to their 403 
apparent structural equivalence). Shown in cyan are residues equivalent to those whose 404 
substitution in the rat α7 nAChR decreases potentiation by ivermectin [64]; only one of these is 405 
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indicated in the GluClR structure, as it is one of the aligned residues in (b). (b) Amino acid 406 
sequence alignment. Colours indicate the residues shown in (a). Circled residues are smaller in 407 
the α7 nAChR than in other cationic receptors, providing a possible explanation for selectivity of 408 
ivermectin for the α7 nAChR over other cationic receptors. Boxed residues are smaller in the α7 409 
nAChR than in anionic Cy-loop receptors, providing a possible explanation for the selectivity of 410 
ivermectin for the M1-M4 site in the former. 411 
 412 
Figure 6. Putative ivermectin-insensitive receptor subunits from trematodes. An amino acid 413 
sequence alignment of characterised GluClR, GlyR, HisCl and GABAAR (UNC-49B) subunits 414 
from vertebrates, insects and nematodes (black) and uncharacterised subunits from trematodes 415 
(purple). Sma, Schistosoma mansoni; Sja, Schistosoma japonicum; Sha, Schistosoma 416 
haematobium; Csi, Clonorchis sinensis; Sme, Schmidtea mediterranea. Loop B is part of the 417 
neurotransmitter binding domain (see Figure 1). A Glu residue at the cyan position is important to 418 
the binding of the agonists glycine, histamine and GABA [71]. Although the putative trematode 419 
subunits possess several features of the ivermectin binding site, such as the M1-Pro (first red 420 
residue) and several polar sidechains (boxed residues), they possess large hydrophobic sidechains 421 
at the M3-Gly position (second red residue), indicative of ivermectin insensitivity. Smp_104890 422 
and Smp_096480 [70] and Sjp_0079260 [79] were retrieved at GeneDB. Sha_300716 was 423 
retrieved from the original publicaton [80]. GAA36399.1 [81] was retrieved from GenBank. 424 
mk4.001914 [82] was retrieved from SmedGD. 425 
426 
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